Intellia Therapeutics (NTLA) Misses Q1 EPS by 19c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Intellia Therapeutics (NTLA) Misses Q1 EPS by 19c, Revenues Miss

Intellia Therapeutics Announces First Quarter 2020 Financial Results

May 7, 2020 7:30 AM EDT

On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose first patient in 2H 2020On track to submit an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001 for the treatment of acute myeloid leukemia, in 1H 2021Nominated NTLA-2002 as development candidate for the treatment of hereditary angioedema; plans to submit an IND or IND-equivalent in 2H 2021IND accepted for CRISPR/Cas9-based sickle cell disease therapeutic candidate developed under collaboration with IntelliaEnded... More